|
|
|
| Observation of the Clinical Effects of Vindesine and Conventional Dose Glucocorticoid on Patients with Immune Thrombocytopenic Purpura |
| DENG Lili |
| Sanya People's Hospital, Hainan Sanya 572000, China |
|
|
|
|
Abstract Objective: To discuss the effects of vindesine and conventional dose glucocorticoid on patients with immune thrombocytopenic purpura. Methods: 50 patients with immune thrombocytopenic purpura were divided into the observation group (n=25) and the control group(n=25), the control group were treated with conventional dose glucocorticoid, the observation group were treated with vindesine and conventional dose glucocorticoid. And the effective rate, PLT levels before and 4 weeks after the treatment, adverse reaction were contrasted between the two groups. Results: The effective rate was 75.0% in the observation group, significantly higher than 48.0% in the control group (P<0.05). PLT was significantly higher 4 weeks after the treatment than before (P<0.05); the PLT in the observation group was significantly higher in the observation group than the control group4 weeks after treatment (P<0.05). There was no significant difference in the adverse reactions between the two groups (P>0.05). Conclusion: Vindesine and conventional dose glucocorticoid has exactly effects in the treatment of patients with immune thrombocytopenic purpura. And it can increase the level of PLT, some patients can achieve long-term remission, and without serious adverse reactions, and the security is high.
|
|
|
|
|
|
[1] 金阿荣.小剂量美罗华联合地塞米松治疗难治性特发性血小板减少性紫癜11例[J].海南医学,2013,24(20):3053~3054.
[2] 肖小兵.亚剂量丙种球蛋白治疗特发性血小板减少性紫癜40例临床疗效观察[J].海南医学,2013,24(5):683~684.
[3] 侯明.我如何治疗糖皮质激素无效或复发的成人原发免疫性血小板减少症[J].中华血液学杂志,2017,38(5):375~378.
[4] 孙彩虹,杜锋蔚,张仪.以神经症状为突出表现的血栓性血小板减少性紫癜临床分析[J].中华急诊医学杂志,2017,26(7):822~823.
[5] Kikuchi K, Miyakawa Y, Ikeda S,et al. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid resistant idiopathic thrombocy topenic purpura in adults[J].BMC Health Serv Res,2015,22:15~16.
[6] 林晓,王志华.妊娠合并遗传性血栓性血小板减少性紫癜治疗经验[J].中华医学杂志,2016,96(17):1386~1387.
[7] Brice Fresneau, Arnaud Petit, Mary-France Courcoux,et al. Vinblas tine in the treatment of children and adolescents with refractory im- mune thrombocytopenia[J]. AM Hematol, 2011,86:785~787.
[8] 何志旭,金姣.儿童常见非特发性血小板减少性紫癜[J].临床儿科杂志,2013,31(5):401~404.
[9] Zhou H, Yang J, Liu L,et al.The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population[J]. Platelets,2015,25:1~6.
[10] 朱芸.特发性血小板减少性紫癜30例回顾性分析[J].影响研究与医学应用,2017,1(11):182~183.
[11] Sikorska A, Slomkowski M, Marlanka K,et al. The use of vinca alka- loids in adult patients with refractory chronic idiopathic thrombocy topenia[J].Clin Lab Haematol, 2004,26:407~411.
[12] 陈晓文.甘露聚糖肽口服液治疗血小板减少性紫癜的疗效观察[J].中国医药指南,2014,34(2):245~246. |
|
|
|
2018, Vol. 24 
